Aurora Cannabis announced its company CanniMed Therapeutics entered into a letter of intent to become a “preferred supplier” of cannabis for medical purposes to Pharmasave.
Aurora Cannabis (TSX:ACB; OTCQB:ACBFF) announced its company CanniMed Therapeutics (TSX:CMED) entered into a letter of intent to become a “preferred supplier” of cannabis for medical purposes to Pharmasave.
As quoted in the press release:
A member governed cooperative of more than 650 independently owned community pharmacies across the country, Pharmasave is one of Canada’s leading independent community pharmacies.
Subject to changes to regulations that would allow such distribution, CanniMed and Aurora will supply and distribute high-quality medical cannabis, produced at the companies’ GMP compliant and GMP certified facilities, through Pharmasave pharmacists across Canada.
“Canadians trust pharmacists to help guide them to the right information and products to treat their conditions,” said Terry Booth, Aurora CEO, “and now Pharmasave joins two other national pharmacy chains in showing their trust in us to provide them with medical cannabis products and education.”